share_log

60 Degrees Pharmaceuticals To Sponsor Pre-Clinical Studies Of Tafenoquine Use In Candida Spp, Including Candida Auris

60 Degrees Pharmaceuticals To Sponsor Pre-Clinical Studies Of Tafenoquine Use In Candida Spp, Including Candida Auris

60 Degrees Pharmicals將贊助他芬諾喹在包括耳念珠菌在內的念珠菌中的用途的臨床前研究
Benzinga ·  02/20 21:09
  • Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals
  • Tafenoquine's presumed mode of action against C. auris is differentiated from standard of care treatment
  • Monash University will conduct the studies beginning in second quarter of 2024
  • 耳念珠菌(C. auris) 是美國醫院中出現的一種危險的耐藥真菌病原體
  • Tafenoquine的假定行動方式 C. auris 與護理治療標準不同
  • 莫納什大學將從2024年第二季度開始研究

WASHINGTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the "Company," "60P" or "60 Degrees Pharmaceuticals") (NASDAQ:SXTP, SXTPW))))), specialists in developing and marketing medicines for infectious diseases, today announced it will, through its majority-owned subsidiary 60P Australia Pty Ltd, sponsor a series of animal studies to investigate whether single dose parenteral administration of tafenoquine exhibits efficacy against Candida spp, including Candida auris (C. auris). C. auris, a strain of fungal yeast, is an emerging pathogen that poses risk of serious infection in the bloodstream and elsewhere, especially in hospitalized patients.

華盛頓,2024年2月20日(GLOBE NEWSWIRE)——傳染病藥物開發和銷售專家60度製藥公司(“公司”,“60P” 或 “60 度製藥”)(納斯達克股票代碼:SXTP,SXTPW))今天宣佈,它將通過其控股子公司60P Australia Pty Ltd贊助一系列動物研究,以調查單劑量是否爲腸胃外注射他芬諾喹的給藥具有抗擊的功效 念珠菌 spp,包括 耳念珠菌 (C. auris)。C。 耳道,一種真菌酵母菌株,是一種新興的病原體,在血液和其他地方構成嚴重感染的風險,尤其是在住院患者中。

The study will be conducted by Monash University in Melbourne, Australia, beginning in the second quarter of 2024. Results are expected by the end of 2024.

該研究將從2024年第二季度開始由澳大利亞墨爾本的莫納什大學進行。結果預計將在2024年底公佈。

Tafenoquine is the active ingredient in an anti-malarial approved by the U.S. Food and Drug Administration (FDA) in 2018 and is indicated for the prophylaxis of malaria in patients aged 18 years of age and older.

他芬諾喹是美國食品藥品監督管理局(FDA)於2018年批准的抗瘧藥物中的活性成分,適用於18歲及以上的患者的瘧疾預防。

"The rapid transmission of Candida auris in healthcare facilities is a very real threat and the need for a safe, effective treatment option is becoming more urgent every day," said 60 Degrees Pharmaceuticals Chief Executive Officer and President, Geoff Dow. "This important study could certainly yield valuable insights into how tafenoquine may be used toward that end. We are pleased to serve as the study sponsor working with Monash University and look forward to reviewing results in coming months."

“的快速傳播 耳念珠菌 60 Degrees Pharmicals首席執行官兼總裁傑夫·道說,醫療機構是一個非常現實的威脅,對安全、有效的治療選擇的需求每天都變得越來越緊迫。“這項重要的研究無疑可以爲如何將他非諾喹用於這一目的提供寶貴的見解。我們很高興作爲研究贊助商與莫納什大學合作,並期待在未來幾個月內審查結果。”

"It is well known that Candida auris can cause severe illness in hospitalized patients," said Professor Anton Peleg, a Professor at Central Clinical School, Monash University, and the principal investigator for the studies. "Even more concerning is the fact that many strains of this fungal infection are now completely resistant to currently available therapies. We are optimistic that the results of our study using tafenoquine will point the way toward development of a new treatment to address this clear, unmet medical need."

“衆所周知 耳念珠菌 可能導致住院患者患重病。” 莫納什大學中央臨床學院教授、這些研究的首席研究員安東·佩萊格教授說。“更令人擔憂的是,這種真菌感染的許多菌株現在對目前可用的療法完全具有耐藥性。我們樂觀地認爲,我們使用他非諾喹的研究結果將爲開發一種新療法指明方向,以滿足這種明顯的、未得到滿足的醫療需求。”

The journal, New Microbes and New Infections recently published non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity against several species of Candida, including C. auris, within in vitro broth culture. That research was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

日記, 新微生物和新感染 最近公佈的非臨床研究結果顯示,他非諾喹對幾種物種表現出廣譜抗真菌活性 念珠菌,包括 C. auris,在體外肉湯培養中。該研究由美國國立衛生研究院(NIH)下屬的國家過敏和傳染病研究所(NIAID)資助。

Like other 8-aminoquinoline antimalarials, tafenoquine is expected to kill fungi by disrupting cellular responses to oxidative stress, differentiating it from other antifungals.

像其他8-氨基喹啉抗瘧藥物一樣,他芬諾喹有望通過破壞細胞對氧化應激的反應來殺死真菌,使其與其他抗真菌藥物區分開來。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論